Cystic Fibrosis Drug Market Overview
The cystic fibrosis drug market was estimated at USD 3.56 billion in xxx. The rising rate of Cystic Fibrosis (CF) coupled with the growing rate of treatment is among the significant reasons that will drive the demand for therapies for cystic fibrillation in the coming years. Furthermore, there is a rise in R&D funding from both public and private organizations as well as a rise in initiatives being undertaken by non-profit organizations, and the existence of favorable reimbursement policies are just a few of the critical elements that are expected to propel the market over the next few years.
An increase in drug combinations in the pipeline of major players is among the major factors predicted to drive Cystic fibrosis drug market. Additionally, an increase in the number of clinical trials that increase the number of patients it targets in conjunction with its existing drug portfolio is one of the factors driving the cystic fibrosis drug market. A growing number of R&D activities will likely drive this market’s growth. Some pipelined medications include (VX-445 + tezacaftor plus IVACAFTOR) PTI-428; QR-010, AZD-5634 POL-6014; and QR-010.
Various non-profit organizations like Cystic Fibrosis Worldwide, Cystic Fibrosis Foundation, Cystic Fibrosis Canada, South African Cystic Fibrosis Trust, and South African Cystic Fibrosis Association are always involved in initiatives related to CF, the main reasons for the increasing demand of Cystic fibrosis drug market. These organizations are investing massive sums of money in finding different treatments for CF and funding the key players’ research and development activities.
Get more information on this report : Download Free Sample Pages
Drug Class Information of Cystic fibrosis drug market
The market is divided into pancreatic enzyme supplement mucolytics and bronchodilators, as well as CFTR modulators according to the class of drugs. The most crucial consideration in CF treatments in maintaining lung function while reducing respiratory infections and clearing the mucus from the airways, coordinating the nutritional therapy, and preventing complications. Kalydeco was the initial CFTR modulator drug released at the end of 2012 U.S. In 2014 it was the sole CFTR modifiable drug on the market.
- This drug class is anticipated to be the fastest-growing sector due to the increased quantity of drugs being developed. The CFTR modulators drug combinations currently in development include:
- Tezacaftor (VX-661)+Ivacaftor
- PTI-428, QR-010
- CTP-656 (Deuterated ivacaftor)
- FDL 169
- GLPG 2222
The Route to Administration Insight
The market can be divided into oral and inhalation routes based on the administration method. The verbal course was responsible for the highest percentage of 63.7 percent in 2016 due to the advantages of its administration, such as accessibility and convenience without the assistance of a medical expert. The growing awareness of emerging economies of the benefits of oral medications that include CFTR inhibitors and pancreatic enzyme supplements is one of the main reasons driving sales of these medications.
Cystic Fibrosis Drug Market by Route of administration
Some approved therapeutics that can be administered orally include CFTR moderators like KALYDECO and ORKAMBI and pancreatic enzyme supplements like Creon/Zenpep, PERTZYE, Ultra, and Violence. A high level of commercialization and a massive demand for these medications for treating CF is predicted to propel the oral drug market. Based on the U.S. patient registry, 2015, Hypertonic saline was recommended for 21.5 percent of children between the ages of 0-3 years old and 41.9 percent of children in the age range of 3 to five years. The growing incidence of CF among infants is a significant reason for the increasing demand for oral formulations of drugs.
An increase in the number of clinical trials that grow the number of patients enrolled is among the primary factors that are expected to increase the market. Additionally, the Cystic fibrosis drug market is anticipated to develop with a high increase of 20.1 percent during the forecast time. An increasing amount of public and private companies investing in this sector is one of the factors that will boost the consumption of oral medications.
Regional insights of Cystic fibrosis Market Report
According to the geographic region, it is classified as North America, Europe, Asia Pacific, Latin America, Middle East & Africa. North America accounted for the most revenue, with USD 2,396.4 million in xxx. CF is prevalent within North America as most of those affected by CF have Caucasian descent. In addition, the efforts of the CF Foundation and Cystic Fibrosis Canada are among the primary reasons that can be the reason for its highest percentage.
But, Asia Pacific is expected to be the fastest-growing region with a high rise of 18.8 percent thus driving Cystic fibrosis Market size. While the prevalence of CF isn’t as frequently documented throughout the Asia Pacific area due to insufficient diagnosis and a lack of particular country-specific Cystic fibrosis patient registers, increasing awareness of CF diseases and treatments is anticipated to grow this segment’s growth during the forecast time. The region’s economic development and the improvement of health facilities are expected to increase the market during the forecast time.
The growing awareness among health professionals and patients about the latest therapeutics available in the market and their benefits over existing drugs is one of the significant factors expected to propel the market over the following years. Currently, the supply of specific medications for Cystic fibrosis is meager, but the increasing approvals and launches of new products in this area are expected to spur expansion.
The major players of Cystic fibrosis drug market are constantly engaged in creating new or combination products for treating cystic fibrosis. Investment in R&D is among the most effective strategies to outdo the market. The leading players in the Cystic fibrosis drug market report include: AbbVie, Inc.; F. Hoffmann-La Roche Ltd.; Gilead; Trikafta ; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alexia; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; Alcresta Therapeutics, Inc.; Allergan; and AstraZeneca.
Detailed Analysis of all major major players such as Abbvie cystic fibrosis market and AbbVie cystic fibrosis data will be covered in the study along with others.
|The year of the base year used to estimate||2021|
|Actual estimates/Historical data||2016- 2021|
|Forecast period||2022 – 2030|
|Cystic fibrosis Market Share representation||Revenues In USD million and CAGR from 2022 through 2030.|
|Regional application||North America, Europe, Asia Pacific, Latin America, Middle East & Africa|
|Country’s coverage||U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa|
|Report coverage||Forecast of revenue, share of company market landscape and growth drivers and the latest trends|
Segments of Cystic fibrosis Market:
- Class Outlook for Drug Class Outlook
- CFTR modulators
- Supplements to pancreatic enzymes
- Route of Administration Outlook
- Oral drugs
- Inhaled drugs
- Regional Outlook
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
- South Africa
MWR’s research methodology is based on extensive use of secondary and primary data sources. The research involves the analysis of various aspects impacting the industry, including the policies of the government, the competitive landscape, the market environment and historical data, as well as current developments in the market technological innovation, emerging technologies, and the advancement of technology in related industries, and potential market risks as well as market barriers and issues.
Market Size Estimation of Cystic fibrosis drug market
Bottom-up and top-down approaches are employed to verify the CF Market size and to estimate the size of the Cystic fibrosis drug market for companies’ regions, regions segment as well as product segments and applications (end users). The market estimates are built on the product’s retail price (excluding discounts offered by the distributor, manufacturer, wholesaler, trader, or).
Partially splits, market shares and breakdown of product segments are calculated based on the weights allocated to each segment based on their usage rate and average sale price. The regional splits of the total product market and sub-segments are determined by the per cent of adoption or use of the particular product within the specific region or country.
Top key players of Cystic fibrosis drug market is determined through secondary data, and the market revenue is determined by secondary and primary approach. Secondary research comprised the study of financial and annual reports of the largest companies. In contrast, primary research involved extensive interviews with opinion makers and experts in the industry like experienced front-line employees, directors, CEOs, and marketing managers.
The market share, percentage splits and Growth Rate, as well as the market structure of the Cystic fibrosis drug market, are calculated from secondary sources and then verified by primary sources. All potential factors that affect the markets are verified by conducting primary analysis, and then analyzed to obtain the final qualitative and quantitative results.
Market Breakdown, Data and Triangulation of Cystic fibrosis drug market
After completing market engineering, including calculations of market statistics, size estimations, forecasting of market breakdown, and data triangulation, a lot of analysis are then conducted to collect details and to confirm the numbers to be verified.
Throughout the entire method of market engineering, top-down and bottom-up methods are were widely used, together with a variety of triangulation techniques for market estimation and forecasting of market trends for the entire market segment and sub-segments . A thorough analysis of quantitative data is also carried out using all the data gathered during the entire market engineering process to present important information throughout the research.
Data Sources of Cystic fibrosis drug market
Secondary sources include annual reports, press releases, non-profit organizations and industry associations, government agencies, customs information, and others. This study focuses on extensive use of secondary sources, directories, databases, and directories like Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones and Company) and trading ECONOMICS and News Network, Statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS and company house documents CAS (American Chemical Society) and investor presentations along with SEC filings of corporations.
Secondary research are utilized to discover and gather details that could be used for a thorough technological, market-oriented and commercial analysis of the product market. It also helps collecting necessary information on the most prominent companies, market classification and segmentation by market trends from the lowest level, and critical technological and market developments.
For the research process, different sources from both the demand and supply sides are being interviewed to collect quantitative and qualitative information. The primary sources on the supply side comprise companies (and their rivals) and opinion leaders, experts from the industry and research institutes, distributors, traders and dealers, raw material suppliers and producers, etc.
The primary sources for demand-side information are industry experts, such as business leaders, sales and marketing directors, directors of innovation and technology supply chain executives, the market (product buyers) and top executives from a variety of key organizations and companies operating globally.
The primary studies are then conducted to find segments, types of segmentation, price ranges, application of the product important company, raw materials supply and demand downstream as well as the status of the industry and its forecast, and the fundamental market dynamics, such as risk factors, influence factors and opportunities obstacles to market entry, trends in the industry, and the strategies of key players.
COVID-19 impact Analysis of Cystic fibrosis drug market
To understand the impact of COVID on the Cystic fibrosis drug market, we must understand the supply chain of the Cystic fibrosis drug market industry and the value chain. By analysing the supply chain, we understand the bottlenecks affecting the industry’s growth. And by analysing the value chain, we understand what value each component adds to the entire industry. We then try to understand the COVID impact has on the industry by trying to find answers to the following questions:
How many jobs have been lost?
How many people have died due to COVID?
How did the Government respond, and what measures Government has taken to revive a Cystic fibrosis drug market industry?
How companies in the Cystic fibrosis drug market have responded to COVID?
What growth rate companies are expecting in the Cystic fibrosis drug market?
We also analyse their annual reports and press releases to understand their
strategies post COVID. Then we move towards the primary research part and contact government officials and industry experts such as CEOs, COOs, Directors, VPs, Directors and Managers to understand what impact COVID has had on their businesses and what they are doing to cope with it.
We also try to understand their views regarding other financial aspects, such as recovery and obstacles in achieving pre-COVID growth and when they expect to achieve it.
Finally, after gathering the info from secondary and primary research, we try to form a model through which we gauge the COVID impact on a particular industry (Cystic fibrosis drug market).
Other MWR Trending Reports